https://www.selleckchem.com/products/solutol-hs-15.html In addition, HA treatment decreased sevoflurane-induced neuronal apoptosis in the hippocampus and alleviated Aβ accumulation. Our results also show that the neuroprotective effect of HA is associated with the activation of Nrf2 signaling. Human neuroblastoma H4 cells were used as a model to examine the protective activity of HA against sevoflurane-induced neurotoxicity. In addition, our results show that the inhibition of Nrf2 by a specific inhibitor or targeting siRNA significantly compromises the attenuating effect of HA on sevoflurane-induced cell apoptosis and Aβ accumulation. Conclusion Our results suggest that HA may function as a neuroprotective agent against sevoflurane-induced neurotoxicity. This article is protected by copyright. All rights reserved.Objective To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and review of the relevant literature. Design A multicentre, randomised, open-label, equivalence trial and a meta-analysis. Setting Tertiary referral hospitals in South Korea. Population Pregnant women with history of spontaneous PTB or short cervical length ( less then 25 mm). Methods Eligible women were screened and randomised at 16-22 weeks of gestation to either receive 200 mg vaginal micronised progesterone daily (vaginal group) or intramuscular injection of 250 mg 17α-hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications of progestogen therapy. This trial was registered at ClinicalTrials.gov (NCT02304237). Main outcome measures PTB before 37 weeks of gestation. Results A total of 266 women were randomly assigned and a total of 247 (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention-to-treat analysis. Risks of PTB before 37 weeks of gestation were not significantly different between the two groups (22.7% versus 25.8%, P